Cannabis and Schizophrenia: Self-Medication and Agonist Treatment
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The first aim of this study is to determine whether a brain reward center (BRC) deficiency in
patients with schizophrenia (SCZ) and cannabis use disorder (CUD) will be normalized when
patients are given cannabis or dronabinol. The second aim will serve to further assess the
effects of dronabinol on symptoms and medication side effects in this population.
Phase:
Phase 1
Details
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Collaborators:
Columbia University Indiana University National Institute on Drug Abuse (NIDA) University of Massachusetts, Worcester University of Vermont